-+ 0.00%
-+ 0.00%
-+ 0.00%

CF PharmTech submits CF017 inhalation drug marketing application in Southeast Asia

PUBT·05/28/2026 00:01:09
Listen to the news
CF PharmTech submits CF017 inhalation drug marketing application in Southeast Asia
  • CF PharmTech submitted a marketing authorization application for CF017, a budesonide inhalation suspension, to a Southeast Asian drug regulator.
  • CF017 won China approval in May 2021; the filing signals a push to expand commercialization outside China.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CF Pharmtech Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260528-12173741), on May 28, 2026, and is solely responsible for the information contained therein.